S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The Small Biotech Scaring Big Pharma (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The Small Biotech Scaring Big Pharma (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The Small Biotech Scaring Big Pharma (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The Small Biotech Scaring Big Pharma (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The Small Biotech Scaring Big Pharma (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The Small Biotech Scaring Big Pharma (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The Small Biotech Scaring Big Pharma (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The Small Biotech Scaring Big Pharma (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Why Your IRA Could Crash on January 16th? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
NASDAQ:HROW

Harrow Health - HROW Stock Forecast, Price & News

$12.38
+0.33 (+2.74%)
(As of 12/2/2022 09:00 PM ET)
Add
Compare
Today's Range
$11.90
$12.51
50-Day Range
$7.61
$12.82
52-Week Range
$5.40
$13.29
Volume
151,900 shs
Average Volume
119,576 shs
Market Capitalization
$335.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Harrow Health MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
37.3% Upside
$17.00 Price Target
Short Interest
Bearish
4.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.90mentions of Harrow Health in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$504,800 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.53) to ($0.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

386th out of 1,033 stocks

Pharmaceutical Preparations Industry

159th out of 502 stocks

HROW stock logo

About Harrow Health (NASDAQ:HROW) Stock

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

HROW Stock News Headlines

Harrow Sells Non-Ophthalmic Compounding Business
HROW Harrow Health, Inc.
Melt Pharmaceuticals files for IPO
Is Harrow Health (HROW) a Wise Investment Choice?
Harrow Health, Inc. (HROW)
See More Headlines
Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

HROW Company Calendar

Last Earnings
11/09/2021
Today
12/05/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HROW
Employees
182
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+37.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-18,010,000.00
Pretax Margin
-25.27%

Debt

Sales & Book Value

Annual Sales
$72.48 million
Cash Flow
$0.06 per share
Book Value
$0.41 per share

Miscellaneous

Free Float
23,210,000
Market Cap
$335.13 million
Optionable
Optionable
Beta
0.36

Key Executives

  • Mr. Mark L. Baum J.D. (Age 49)
    CEO & Chairman
    Comp: $1.07M
  • Mr. Andrew R. Boll C.F.A. (Age 40)
    C.M.A., CFA, CMA, CFO & Corp. Sec.
    Comp: $716.73k
  • Dr. Robert J. Kammer D.D.S. (Age 73)
    Special Advisor
    Comp: $91.88k
  • Mr. John P. Saharek MBA (Age 62)
    Chief Commercial Officer
    Comp: $621.92k
  • Jamie Webb
    Director of Communications & Investor Relations
  • Dr. Dennis E Saadeh Pharm.D.
    Chief of Formulation Strategy
  • Mr. Andrew Livingston
    Chief Innovation Officer
  • Ms. Kim Barratt
    Chief Talent Officer













HROW Stock - Frequently Asked Questions

Should I buy or sell Harrow Health stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" HROW shares.
View HROW analyst ratings
or view top-rated stocks.

What is Harrow Health's stock price forecast for 2023?

1 Wall Street research analysts have issued twelve-month price targets for Harrow Health's stock. Their HROW share price forecasts range from $17.00 to $17.00. On average, they expect the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 37.3% from the stock's current price.
View analysts price targets for HROW
or view top-rated stocks among Wall Street analysts.

How have HROW shares performed in 2022?

Harrow Health's stock was trading at $8.64 at the beginning of 2022. Since then, HROW stock has increased by 43.3% and is now trading at $12.38.
View the best growth stocks for 2022 here
.

Are investors shorting Harrow Health?

Harrow Health saw a increase in short interest in November. As of November 15th, there was short interest totaling 993,800 shares, an increase of 15.8% from the October 31st total of 858,200 shares. Based on an average daily volume of 201,200 shares, the short-interest ratio is presently 4.9 days. Approximately 4.0% of the company's shares are sold short.
View Harrow Health's Short Interest
.

When is Harrow Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our HROW earnings forecast
.

How were Harrow Health's earnings last quarter?

Harrow Health, Inc. (NASDAQ:HROW) announced its earnings results on Tuesday, November, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.34. The company earned $18.71 million during the quarter, compared to the consensus estimate of $17.27 million. Harrow Health had a negative trailing twelve-month return on equity of 11.57% and a negative net margin of 25.50%. During the same quarter last year, the firm earned $0.32 EPS.

What other stocks do shareholders of Harrow Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).

What is Harrow Health's stock symbol?

Harrow Health trades on the NASDAQ under the ticker symbol "HROW."

Who are Harrow Health's major shareholders?

Harrow Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.11%), Private Capital Management LLC (3.80%), Ophir Asset Management Pty Ltd (3.17%), Uniplan Investment Counsel Inc. (2.56%), Invenire Partners LP (1.68%) and BlackRock Inc. (1.61%). Insiders that own company stock include David P Kennedy, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom.
View institutional ownership trends
.

How do I buy shares of Harrow Health?

Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harrow Health's stock price today?

One share of HROW stock can currently be purchased for approximately $12.38.

How much money does Harrow Health make?

Harrow Health (NASDAQ:HROW) has a market capitalization of $335.13 million and generates $72.48 million in revenue each year. The company earns $-18,010,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

How many employees does Harrow Health have?

The company employs 182 workers across the globe.

How can I contact Harrow Health?

Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The official website for the company is www.harrowinc.com. The company can be reached via phone at (615) 733-4730, via email at jwebb@harrowinc.com, or via fax at 858-345-1745.

This page (NASDAQ:HROW) was last updated on 12/5/2022 by MarketBeat.com Staff